Pharma BD Deal Intelligence
Novartis's $16B acquisition of GSK's oncology portfolio delivered Tafinlar and Mekinist, two marketed melanoma drugs, in the 2014 three-part asset swap—a rare clean win where Novartis paid for approved revenue-generating assets rather than pipeline promise, and got exactly that in return.
Novartis and GSK complete oncology and vaccines swap, with Novartis acquiring GSKs oncology products including kidney cancer therapy Votrient and breast cancer…
GSK acquired Novartis' oncology division for $16B.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Novartis acquired GSK's oncology portfolio for $16B as part of the 2014 three-part asset swap between GSK and Novartis.
76K US cases/yr · $5.0B Global Targeted Melanoma Market (2014) · $16B Total Deal Value (GSK Oncology to Novartis)
Novartis acquired GSK's entire oncology portfolio for $16B, gaining a strong position in targeted melanoma therapy with Tafinlar (dabrafenib, BRAF inhibitor) and Mekinist (trametinib, MEK inhibitor). The BRAF+MEK combination became standard of care in BRAF-mutant melanoma and later expanded to NSCLC and anaplastic thyroid cancer.
In BRAF-mutant melanoma, the Tafinlar+Mekinist combination competed with Roche/Genentech's Zelboraf+Cotellic (vemurafenib/cobimetinib) and later Pfizer's Braftovi+Mektovi (encorafenib/binimetinib). Additionally, immuno-oncology (Keytruda, Opdivo, ipilimumab) increasingly became the preferred first-line approach, pushing BRAF-targeted therapy to later lines or combination strategies. The GSK portfolio also included Votrient (pazopanib) for RCC/sarcoma.
Novartis announces acquisition of GSK oncology drugs as part of three-way asset exchange.
FTC approves with conditions requiring divestiture of certain overlapping oncology assets.
Tafinlar+Mekinist combo shows significant overall survival benefit in BRAF+ melanoma ahead of close.
Novartis acquires GSK oncology portfolio (Tafinlar, Mekinist, Votrient, Promacta) for up to $16B.
Novartis Oncology grows to 22 hematology/oncology medicines treating 25+ conditions.
GSK oncology assets (esp Tafinlar/Mekinist) became foundation of Novartis oncology expansion.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / GlaxoSmithKline plc (this deal) | 2014 | $16.0B | 81 |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
| Novartis AG / Hexal AG | 2002 | $8.3B | 75 |
← Browse all deals · How we score deals
More: 2014 deals · Novartis AG deals · Oncology deals